Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dame Kay Davies, Dr Lee’s Professor of Anatomy here in DPAG, has been working on a clinical trial that today announced a potentially life-changing discovery.

Summit Therapeutics, the drug discovery and development company advancing therapies for rare diseases and infectious diseases, for which Professor Davies is a co-founder, have released the interim results from the trial, PhaseOut DMD, which had been evaluating the effect of ezutromid in patients with Duchenne muscular dystrophy, DMD.

Discoveries show that ezutromid does indeed reduce muscle damage significantly in DMD patients; a total of 14 out of 22 patients showed a decrease in developmental myosin, a biomarker of muscle damage, with five of those patients showing a greater than 40% reduction.

DMD is a progressive muscle wasting disease that affects around 50,000 boys and young men in the developed world. The results from the trial suggest a potential universal treatment for DMD, since there is currently no cure for DMD and life expectancy is into the late twenties.

Professor Davies is delighted at the results from the trial, saying: These data provide the first evidence of utrophin modulation working in patients. If further findings build on this evidence they could establish ezutromid as a universal, disease-modifying treatment and bring hope to all patients and families living with DMD.

Similar stories

Inaugural Fellowship to Charmaine Lang paves the way to improved human models for Parkinson's drug discovery

Congratulations are in order for Departmental Research Lecturer Dr Charmaine Lang who has been awarded the first jointly funded Senior Research Fellowship from Parkinson’s UK and Rosetrees Trust. With this award, Dr Lang will develop complex new induced pluripotent stem cell (iPSC) models that target the interaction between dopamine neurons and astrocytes in the brain and how these fail in the context of Parkinson's.

New blood test from DPAG cardiac researchers could save lives of heart attack victims

Researchers from the Herring group have developed a blood test that measures stress hormone levels after heart attacks. The test – costing just £10 – could ensure patients receive timely life-saving treatment.

Mootaz Salman set to target new treatments for stroke

The Chief Scientist Office of the Government of Scotland has awarded a collaborative grant of £298,966 to Dr Mootaz Salman to seek new therapeutic avenues to treat stroke.

Mootaz Salman receives prestigious science award from Iraq

Congratulations are in order for Dr Mootaz Salman, who has received the National Medal of Distinctive Scientific Achievement by the Government of Iraq.

Professor Dame Frances Ashcroft awarded the Manpei Suzuki International Prize for Diabetes Research

The 2022 Manpei Suzuki International Prize for Diabetes Research recognises original and excellent achievements in diabetes research. Professor Ashcroft is the first women to win in the 15 years this prestigious Prize has been awarded.